Mayo Clinic HeartShare Clinical Center
梅奥诊所 HeartShare 临床中心
基本信息
- 批准号:10679096
- 负责人:
- 金额:$ 28.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-10 至 2026-07-31
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAdipose tissueAlgorithmsArtificial IntelligenceAutomobile DrivingBeliefBiologicalBusinessesCardiacCardiovascular DiseasesClinicClinicalClinical DataClinical InvestigatorClinical ResearchClinical TrialsCollaborationsCommunitiesComplexConsensusDataData CollectionData ScienceData ScientistData SetDedicationsDiagnosisDiseaseEFRACEnrollmentEtiologyFunctional disorderFutureGenerationsGoalsHeartHeart failureImmersionIndustryInternshipsIntervention TrialMachine LearningMedicalMethodsMissionModelingMuscleMyocardialOrganPatient RecruitmentsPatientsPatternPhenotypePhysiologicalProcessProductivityProgram DevelopmentProteinsProteomicsProtocols documentationPublic HealthResearchResearch PersonnelResourcesScienceSkeletal MuscleSpecific qualifier valueSystemic diseaseTechnologyTestingTherapeuticTranslationsUnited States National Institutes of Healthaptamercirculating biomarkersclinical centerclinical practicecomplex dataeffective therapyexperiencehemodynamicslarge datasetsmachine learning modelnovel diagnosticsnovel markernovel therapeutic interventionpatient retentionpreservationprogramssenescenceskill acquisitionsuccesssupervised learningtargeted agenttargeted treatmentunsupervised learning
项目摘要
PROJECT SUMMARY/ABSTRACT
This is Mayo Clinic’s application to participate in the NIH HeartShare Research Consortium as a HeartShare
Clinical Center (CC). Our goal is to collaborate with the other HeartShare Investigators to elucidate the
pathophysiology of heart failure (HF) with preserved ejection fraction (HFpEF) and discover novel diagnostic
and therapeutic approaches. Multiple pathophysiologic processes may ultimately lead to different HFpEF
phenotypes, though the specific mechanisms remain largely undefined. It is also not known whether standard
clinical information can identify patients with different mechanistic etiologies, which is necessary to provide
targeted therapies in clinical trials and eventually in clinical practice. Our proposal outlines four specific aims. In
Specific Aim 1: We document that Mayo Clinic has the resources and the Mayo HeartShare Team has the
expertise and track record of productivity in HFpEF and relevant related diseases, clinical research, patient
recruitment and retention, data science, and collaborative team science to help drive the success of
HeartShare Network. In Specific Aim 2: We propose a broad mechanistic phenotyping protocol providing
quantitative variables reflective of senescence, systemic disease processes, and multi-organ integrity (L2
data), which are used as input variables in unsupervised machine learning (ML) models. We hypothesize that
this approach will allow identification of unique HFpEF pathophysiologic phenogroups (clusters). We also
propose invasive hemodynamic signatures, trans-cardiac gradients of circulating biomarkers and myocardial,
adipose and skeletal muscle tissue characterization (L3 data) be obtained in a subset within each HFpEF
pathophysiologic phenogroup. We hypothesize these L3 data will enhance identification of targeted therapeutic
strategies. Lastly, we outline supervised ML using EHR data to develop automatable algorithms to accurately
identify the HeartShare HFpEF pathophysiological phenogroups derived using L2 data. We hypothesize that if
successful, this approach will enhance translation of HeartShare findings by allowing automated identification
of patients in the different HFpEF phenogroups for enrollment in clinical trials of agents targeting their specific
pathophysiology. In Specific Aim 3: We propose that use of circulating proteins alone (n=5000; defined by the
SOMAScanTM Aptamer based platform) as input variables for unsupervised ML models will identify unique
HFpEF pathophysiologic phenotypes (clusters). In Specific Aim 4: We outline the Mayo HeartShare Research
Skills Development Program. Providing HFpEF clinical investigators a short-term intensive immersion
experience by collaboration with a data scientist intern in the Mayo Cardiovascular Disease AI Internship or
a long term dedicated program in data science as a Mayo Kern Center Scholar in Data Science will equip a
new generation of HFpEF investigators with a robust data science toolbox to drive future discovery.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Barry A. Borlaug其他文献
Impact of Epicardial Adipose Tissue in Heart Failure with Preserved Ejection Fraction
- DOI:
10.1016/j.cardfail.2018.07.018 - 发表时间:
2018-08-01 - 期刊:
- 影响因子:
- 作者:
Katlyn E. Koepp;Masaru Obokata;Yogesh N. Reddy;Thomas P. Olson;Barry A. Borlaug - 通讯作者:
Barry A. Borlaug
Heart Failure With Preserved Ejection Fraction: emJACC/em Scientific Statement
射血分数保留的心力衰竭:emJACC/em 科学声明
- DOI:
10.1016/j.jacc.2023.01.049 - 发表时间:
2023-05-09 - 期刊:
- 影响因子:22.300
- 作者:
Barry A. Borlaug;Kavita Sharma;Sanjiv J. Shah;Jennifer E. Ho - 通讯作者:
Jennifer E. Ho
Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy
替尔泊肽可降低肥胖相关性心力衰竭患者的左心室质量和心周脂肪组织:SUMMIT CMR 亚研究
- DOI:
10.1016/j.jacc.2024.11.001 - 发表时间:
2025-02-25 - 期刊:
- 影响因子:22.300
- 作者:
Christopher M. Kramer;Barry A. Borlaug;Michael R. Zile;Dustin Ruff;Joseph M. DiMaria;Venu Menon;Yang Ou;Angela M. Zarante;Karla C. Hurt;Masahiro Murakami;Milton Packer;SUMMIT Trial Study Group - 通讯作者:
SUMMIT Trial Study Group
Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Program
心房颤动与司美格鲁肽在射血分数保留的肥胖相关性心力衰竭中的作用:STEP-HFpEF项目
- DOI:
10.1016/j.jacc.2024.08.023 - 发表时间:
2024-10-22 - 期刊:
- 影响因子:22.300
- 作者:
Subodh Verma;Javed Butler;Barry A. Borlaug;Melanie J. Davies;Dalane W. Kitzman;Mark C. Petrie;Sanjiv J. Shah;Thomas Jon Jensen;Søren Rasmussen;Cecilia Rönnbäck;Bela Merkely;Evan O’Keefe;Mikhail N. Kosiborod;STEP-HFpEF and STEP-HFpEF DM Investigators - 通讯作者:
STEP-HFpEF and STEP-HFpEF DM Investigators
HEMODYNAMIC RESPONSES TO ARTERIAL VASODILATION FUNDAMENTALLY DIFFER IN HEART FAILURE WITH PRESERVED VERSUS REDUCED EJECTION FRACTION
- DOI:
10.1016/s0735-1097(11)60196-4 - 发表时间:
2011-04-05 - 期刊:
- 影响因子:
- 作者:
Shmuel Schwartzenberg;Margaret M. Redfield;Aaron M. From;Sorajja Paul;Rick A. Nishimura;Barry A. Borlaug - 通讯作者:
Barry A. Borlaug
Barry A. Borlaug的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Barry A. Borlaug', 18)}}的其他基金
HL-Inorganic Nitrite to Enhance Benefits from Exercise Training in Heart Failure with preserved Ejection Fraction
HL-无机亚硝酸盐可增强心力衰竭运动训练的益处并保留射血分数
- 批准号:
9252549 - 财政年份:2016
- 资助金额:
$ 28.1万 - 项目类别:
HL-Inorganic Nitrite to Enhance Benefits from Exercise Training in Heart Failure with preserved Ejection Fraction
HL-无机亚硝酸盐可增强心力衰竭运动训练的益处并保留射血分数
- 批准号:
9459406 - 财政年份:2016
- 资助金额:
$ 28.1万 - 项目类别:
相似海外基金
Deciphering the role of adipose tissue in common metabolic disease via adipose tissue proteomics
通过脂肪组织蛋白质组学解读脂肪组织在常见代谢疾病中的作用
- 批准号:
MR/Y013891/1 - 财政年份:2024
- 资助金额:
$ 28.1万 - 项目类别:
Research Grant
ESTABLISHING THE ROLE OF ADIPOSE TISSUE INFLAMMATION IN THE REGULATION OF MUSCLE MASS IN OLDER PEOPLE
确定脂肪组织炎症在老年人肌肉质量调节中的作用
- 批准号:
BB/Y006542/1 - 财政年份:2024
- 资助金额:
$ 28.1万 - 项目类别:
Research Grant
Canadian Alliance of Healthy Hearts and Minds: Dissecting the Pathways Linking Ectopic Adipose Tissue to Cognitive Dysfunction
加拿大健康心灵联盟:剖析异位脂肪组织与认知功能障碍之间的联系途径
- 批准号:
479570 - 财政年份:2023
- 资助金额:
$ 28.1万 - 项目类别:
Operating Grants
Determinants of Longitudinal Progression of Adipose Tissue Inflammation in Individuals at High-Risk for Type 2 Diabetes: Novel Insights from Metabolomic Profiling
2 型糖尿病高危个体脂肪组织炎症纵向进展的决定因素:代谢组学分析的新见解
- 批准号:
488898 - 财政年份:2023
- 资助金额:
$ 28.1万 - 项目类别:
Operating Grants
Activation of human brown adipose tissue using food ingredients that enhance the bioavailability of nitric oxide
使用增强一氧化氮生物利用度的食品成分激活人体棕色脂肪组织
- 批准号:
23H03323 - 财政年份:2023
- 资助金额:
$ 28.1万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of new lung regeneration therapies by elucidating the lung regeneration mechanism of adipose tissue-derived stem cells
通过阐明脂肪组织干细胞的肺再生机制开发新的肺再生疗法
- 批准号:
23K08293 - 财政年份:2023
- 资助金额:
$ 28.1万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A study on the role of brown adipose tissue in the development and maintenance of skeletal muscles
棕色脂肪组织在骨骼肌发育和维持中作用的研究
- 批准号:
23K19922 - 财政年份:2023
- 资助金额:
$ 28.1万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Adipose Tissue T Cell Polarization and Metabolic Health in Persons Living with HIV
HIV 感染者的脂肪组织 T 细胞极化和代谢健康
- 批准号:
10619176 - 财政年份:2023
- 资助金额:
$ 28.1万 - 项目类别:
Estrogen Signaling in the Ventromedial Hypothalamus Modulates Adipose Tissue Metabolic Adaptation
下丘脑腹内侧区的雌激素信号调节脂肪组织代谢适应
- 批准号:
10604611 - 财政年份:2023
- 资助金额:
$ 28.1万 - 项目类别:
Obesity and Childhood Asthma: The Role of Adipose Tissue
肥胖和儿童哮喘:脂肪组织的作用
- 批准号:
10813753 - 财政年份:2023
- 资助金额:
$ 28.1万 - 项目类别: